One-shot gene editing for LDL.

One-shot gene editing for LDL. “One dose of VERVE-102 led to dose-dependent, substantial, and sustained reductions in PCSK9 and LDL cholesterol levels.” It is a phase 1 study in 35 people, with LDL reductions up to 62% at the highest dose and durability out to at least a year for some participants. ~ learn more